• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [21797 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Neuromuscular feedback therapy for paraplegia (Addendum to Commission E21-08)]
2022     Canary Health Service [Portable neuromodulation stimulation device to improve gait in multiple sclerosis]
2022     Canary Health Service [Implantable neurostimulation device for the treatment of drug-resistant pediatric epilepsy]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Magnetic sphincter augmentation for gastrooesophageal reflux disease]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Magnetic sphincter augmentation for gastrooesophageal reflux disease (Addendum to Commission E21-06)]
2022     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Effectiveness of social distancing measures, in the context of the COVID-19]
2022     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Safety and effectiveness of percutaneous tricuspid valve repair]
2022     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Systematic review on diagnosis and care of reactive attachment disorder]
2022     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Efficacy and safety of transanal irrigation in adults with bowel dysfunction]
2022     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Evaluation of several vaccination strategies against rotavirus in Spain. Safety, efficacy, effectiveness and efficiency]
2022     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Use of indocyanine green in colorectal and hepato-biliopancreatic surgery]
2022     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Cardiac monitoring with textile wearable Holter for atrial fibrillation detection after cryptogenic stroke]
2022     Institute for Clinical and Economic Review (ICER) The next generation of rare disease drug policy: ensuring both innovation and affordability
2022     Institute for Clinical and Economic Review (ICER) California unsupported price increase report; an evaluation of drug price increases during 2020 in California
2022     Institute for Clinical and Economic Review (ICER) Unsupported price increase report: unsupported price increases occurring in 2021
2022     Institute for Clinical and Economic Review (ICER) Novel agents to prevent chemotherapy-induced neutropenia and other myelosuppressive effects [updated Sept 29, 2023]
2022     Institute for Clinical and Economic Review (ICER) AMX0035 and oral edaravone for amyotrophic lateral sclerosis
2022     Institute for Clinical and Economic Review (ICER) Medications for obesity management: effectiveness and value
2022     Canadian Agency for Drugs and Technologies in Health (CADTH) Systemic thrombolysis and endovascular therapy for large vessel occlusion acute ischemic stroke
2022     Canadian Agency for Drugs and Technologies in Health (CADTH) Systemic thrombolysis by alteplase for acute ischemic stroke
2022     Canadian Agency for Drugs and Technologies in Health (CADTH) Dapagliflozin for chronic kidney disease
2022     Canadian Agency for Drugs and Technologies in Health (CADTH) Internet-delivered cognitive behavioural therapy in the treatment of chronic non-cancer pain
2022     Canadian Agency for Drugs and Technologies in Health (CADTH) Peer support programs for youth mental health
2022     Canadian Agency for Drugs and Technologies in Health (CADTH) Adalimumab for the treatment of pediatric populations with non-infectious uveitis
2022     Canadian Agency for Drugs and Technologies in Health (CADTH) Adalimumab for the treatment of adults with non-infectious uveitis
2022     Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Pulmonary rehabilitation in people with chronic obstructive pulmonary disease (a briefing note)]
2022     Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Anesthesia information management systems]
2022     Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Procalcitonin assay for optimizing the use of antibiotics in the treatment of infections]
2022     Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Screening tools for frailty in users undergoing cardiac surgery requiring a sternotomy]
2022     Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Respiratory rehabilitation following hospitalization related to a diagnosis of COVID-19 - an update]
2022     Agency for Healthcare Research and Quality (AHRQ) Transitions of care from pediatric to adult services for children with special healthcare needs
2022     Agency for Healthcare Research and Quality (AHRQ) Telehealth for women's preventive services
2022     Agency for Healthcare Research and Quality (AHRQ) Schedule of visits and televisits for routine antenatal care
2022     Agency for Healthcare Research and Quality (AHRQ) Noninvasive nonpharmacological treatment for chronic pain
2022     Agency for Healthcare Research and Quality (AHRQ) Models of care that include primary care for adult survivors of childhood cancer: a realist review
2022     Agency for Healthcare Research and Quality (AHRQ) Maternal and child outcomes associated with the Special Supplemental Nutrition Program for women, infants, and children (WIC)
2022     Agency for Healthcare Research and Quality (AHRQ) Management of infantile epilepsies
2022     Agency for Healthcare Research and Quality (AHRQ) Infection prevention and control for the emergency medical services and 911 workforce
2022     Agency for Healthcare Research and Quality (AHRQ) Improving rural health through telehealth-guided provider-to-provider communication
2022     Agency for Healthcare Research and Quality (AHRQ) Evaluation of mental health mobile applications
2022     Agency for Healthcare Research and Quality (AHRQ) Diagnostic errors in the emergency department: a systematic review
2022     Agency for Healthcare Research and Quality (AHRQ) Antibody response following SARS-CoV-2 infection and implications for immunity: a living rapid review
2022     Agency for Healthcare Research and Quality (AHRQ) Acute treatments for episodic migraine
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Digital breast tomosynthesis]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Irreversible electroporation in pancreatic cancer]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Treprostinil in chronic thromboembolic pulmonary hypertension (group 4)]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Newsletter: drug costs -tracking Quebec spending and trends]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Newsletter: experiences and lessons learned with conditional refund terms]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Newsletter: overview of early access mechanisms and conditional refund terms]
2022     The Federal Joint Committee (G-BA) Pharmaceutical Directive/Annex XII: Pegcetacoplan (paroxysmal nocturnal haemoglobinuria, pretreated patients)
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report: V21-12G: Routine follow-up examination: evidence report for the S3 guideline on abortion in the first trimester]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report: V21-12F: Anti-D prophylaxis: evidence report for the S3 guideline on abortion in the first trimester]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report: V21-12D: Antibiotic prophylaxis: evidence report for the S3 guideline on abortion in the first trimester]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report: V21-12C: Surgical abortion: evidence report for the S3 guideline on abortion in the first trimester]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission "Low-intensity pulsed ultrasound for the treatment of pseudarthrosis"]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Low-intensity pulsed ultrasound for the treatment of pseudarthrosis]
2022     Health Sciences Institute in Aragon (IACS) [Digital dermatoscopy]
2022     Canary Health Service [Influenza vaccination in children 6 to 59 months of age]
2022     Canary Health Service [Artificial pancreas with dual release of insulin and pramlintide for treatment of type 1 diabetes mellitus]
2022     Finnish Coordinating Center for Health Technology Assessment (FinCCHTA) Suvanto Care Safety Service
2022     Finnish Coordinating Center for Health Technology Assessment (FinCCHTA) Unipercare service for home care and service centres
2022     Finnish Coordinating Center for Health Technology Assessment (FinCCHTA) The Orla INR Remote Monitoring
2022     Finnish Coordinating Center for Health Technology Assessment (FinCCHTA) Hygga Flow Enterprise Resource Planning System
2022     Finnish Coordinating Center for Health Technology Assessment (FinCCHTA) Monidor solution for the implementation of intravenous fluid therapy
2022     Finnish Coordinating Center for Health Technology Assessment (FinCCHTA) Smila Care Service
2022     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) The utilization and national variation of plain x-ray services by Australian residents of long-term care facilities
2022     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Residents' perspectives of mobile X-ray services in support of healthcare-in-place in residential aged care facilities: a qualitative study.
2022     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Stakeholders' perspectives of mobile x-ray services in support of healthcare-in-place in residential aged care facilities: a qualitative study
2022     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Update: guidelines on the preoperative diagnostic workup for COVID-19
2022     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Mesh versus non-mesh repair of groin hernias: a rapid review
2022     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Impact of COVID-19, gender, race, specialty and seniority on mental health during surgical training: an international study
2022     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Achieving safe surgery after COVID-19 vaccination
2022     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Quality improvement strategies in trauma care: review and proposal of 31 novel quality indicators
2022     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Hepatic and portal vein embolization prior to major hepatectomy
2022     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Microwave ablation for liver tumours
2022     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Oral anticoagulants for prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation. [Protocol]
2022     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Calcitonin gene-related peptide antagonists for the prevention of migraine [Protocol]
2022     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Denosumab (Prolia) for the treatment of osteoporosis
2022     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Revascularisation versus optimal medical therapy (OMT) for the treatment of chronic coronary syndrome (CCS). [Protocol]
2022     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Folate testing. [Protocol]
2022     Canary Health Service [Effectiveness and safety of meditation]
2022     Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale (CIUSSS) [Palliative care day centre service offer for users and caregivers]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Number of tonsillitis episodes: evidence report for the S3 guideline on treatment of inflammatory diseases of the palatine tonsils/tonsillitis]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (oesophageal carcinoma, combination with chemotherapy) - Addendum to Commission A22-54]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (urothelial carcinoma, adjuvant) - Addendum to Commission A22-53]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (bile cancer) - Benefit assessment according to § 35a SGB V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (small bowel cancer) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Voxelotor (sickle cell disease) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Glucarpidase (toxic MTX plasma concentrations) - Assessment according to §35a SGB V (1), Sentence 11]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (endometrial carcinoma) - Addendum to Commission A21-164]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lenvatinib (endometrial carcinoma) - Addendum to Commission A21-162]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Casirivimab/imdevimab (COVID-19) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dupilumab (severe asthma with type 2 inflammation) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Duvelisib (follicular lymphoma) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Duvelisib (chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Burosumab (X-linked hypophosphataemia, = 18 years) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Burosumab (X-linked hypophosphataemia) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Isoflurane (sedation of mechanically ventilated patients) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Calcifediol (secondary hyperparathyroidism) - Benefit assessment according to §35a Social Code Book V]
2022     Scottish Health Technologies Group (SHTG) A national radiology information system (RIS) for Scotland: perceived benefits and constraints to implementation